Search
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsVarespladib
go.drugbank.com/drugs/DB11909InvestigationalVarespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.
Categories: Heterocyclic Compounds, 2-Ring, Phospholipases A, antagonists & inhibitorsValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: REMLEAS™ hard capsules 40mgSafingol
go.drugbank.com/drugs/DB11924InvestigationalSafingol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Protein Kinase C, antagonists & inhibitorsDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.
Categories: Heterocyclic Compounds, 1-RingHenagliflozin
go.drugbank.com/drugs/DB11939InvestigationalHenagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalGlasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsThiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approvedA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedioneChloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative. … [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration, similar to the one observed with [lidocaine].
Synonyms: 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate, 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl esterProducts: Nesacaine Ce 2% Inj 20mg/ml, Nesacaine Ce 3% Inj 30mg/ml